Tobramycin is a new aminoglycoside antibiotic with activity against a wide range of bacteria. More than 90% of coliform organisms and Pseudomonas were susceptible in vitro to 5μg/ml of tobramycin. Pharmacokinetic properties of tobramycin in neonates are similar to those of gentamicin. Peak levels of 4μg to 6μg/ml are achieved in serum after a dose of 2.0 mg/kg; it can be given every 12 hours for up to ten days without accumulation. Serum half-life values were inversely related to birth weights and creatinine clearances. It is suggested that tobramycin be used only for the treatment of neonatal infections caused by tobramycin-susceptible gram-negative organisms resistant to both kanamycin and gentamicin. Studies of clinical efficacy and toxicity in neonates are necessary before the drug can be recommended for routine use.
Kaplan JM, McCracken GH, Thomas ML, Horton LJ, Davis N. Clinical Pharmacology of Tobramycin in Newborns. Am J Dis Child. 1973;125(5):656-660. doi:10.1001/archpedi.1973.04160050012003